Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
Maurizio
M
Zangari
Jose
J
Guerrero
Federica
F
Cavallo
H Keshava
HK
Prasad
Dixie
D
Esseltine
Louis
L
Fink
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D005165:Factor V / Q000378:metabolism; D005260:Female; D006487:Hemostasis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology*; D010865:Pilot Projects; D010974:Platelet Aggregation / Q000187:drug effects; D011486:Protein C / Q000378:metabolism; D011719:Pyrazines / Q000627:therapeutic use*; D012008:Recurrence; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011486:Protein C; D011719:Pyrazines; D000069286:Bortezomib; D005165:Factor V